FILE PHOTO: A vial of Pfizer/BioNTech coronavirus vaccine is pictured at a vaccination centre inside Harpenden Public Halls, amid the outbreak of the coronavirus disease (COVID-19) in Harpenden, Britain, January 22, 2021. REUTERS/Peter Cziborra
CHICAGO (Reuters) - After developing and rolling out COVID-19 vaccines at record speed, drugmakers are already facing variants of the rapidly-evolving coronavirus that may render them ineffective, a challenge that will require months of research and a massive financial investment, according to disease experts.
Executives from Moderna Inc and Pfizer Inc and partner BioNTech SE are considering new versions of their vaccines to respond to the most concerning variants identified so far. That is just one piece of the work needed to stay ahead of the virus, nearly a dozen experts told Reuters.
Limited time offer:
Just RM5 per month.
